Patents Examined by Celine X. Qian
  • Patent number: 11827881
    Abstract: This disclosure provides systems, methods, and compositions for site-specific genetic engineering using Programmable Addition via Site-Specific Targeting Elements (PASTE). PASTE comprises the addition of an integration site into a target genome followed by the insertion of one or more genes of interest or one or more nucleic acid sequences of interest at the site. PASTE combines gene editing technologies and integrase technologies to achieve unidirectional incorporation of genes in a genome for the treatment of diseases and diagnosis of disease.
    Type: Grant
    Filed: December 14, 2022
    Date of Patent: November 28, 2023
    Assignee: Massachusetts Institute of Technology
    Inventors: Omar Abudayyeh, Jonathan Gootenberg
  • Patent number: 11820989
    Abstract: The invention relates to C. acnes carrying DNA vectors with a C. acnes phage packaging signal and a gene of interest. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a C. acnes phage packaging signal and a gene of interest, for the production of phage-derived particles that can robustly transduce C. acnes receiver cell allowing transgene expression. The invention encompasses C. acnes phage-derived particles carrying these vectors, C. acnes containing these vectors or modified by transduction of these phage-derived particles, and methods of using these phage-derived particles.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: November 21, 2023
    Assignee: Eligo Bioscience
    Inventors: Aymeric Leveau, Inès Canadas Blasco, Aurélie Mathieu, Antoine Decrulle
  • Patent number: 11793890
    Abstract: Disclosed herein are therapeutic agents capable of increasing the expression level of ELOVL2. Also described herein are therapeutic agents that reduce or slow an aging phenotype. Methods for treating age-related eye diseases or conditions are also provided. Methods for treating an age-related eye disease or condition in a subject by administering one or more therapeutic agents are provided.
    Type: Grant
    Filed: August 24, 2022
    Date of Patent: October 24, 2023
    Assignee: Visgenx, Inc.
    Inventors: Christopher Chavez, Martin Emanuele
  • Patent number: 11788102
    Abstract: Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: October 17, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Ying Shen, Darya Burakov, Gang Chen, James P. Fandl
  • Patent number: 11753624
    Abstract: The various embodiments of the disclosure relate generally to processes, methods, and systems for generating functional B cells ex vivo. It is particularly useful for ex vivo generation of antigen-specific germinal-center (GC) like B cells that are capable of efficient B cell expansion, immunoglobulin (Ig) class switching/class switching recombination (CSR), expression of germinal B cell phenotypes, antibody secretion, and somatic hypermutation (SHM) and resulting affinity maturation center phenotypes.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: September 12, 2023
    Assignee: Georgia Tech Research Corporation
    Inventors: Krishnendu Roy, Kyung-Ho Roh
  • Patent number: 11753667
    Abstract: The present invention is directed to methods and materials for RNA-mediated gene assembly from oligonucleotide sequences. In some embodiments, the oligonucleotides used for gene assembly are provided in an array format. An RNA polymerase promoter is appended to surface-bound oligonucleotides and a plurality of RNA copies of each oligonucleotide are then produced with an RNA polymerase. These RNA molecules self-assemble into a desired full-length RNA transcript by hybridization and ligation. The resulting RNA transcript may then be converted into double stand DNA useful in a variety of applications including protein expression.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: September 12, 2023
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Cheng-Hsien Wu, Lloyd Smith
  • Patent number: 11746162
    Abstract: Provided herein are compositions and methods for assembling nucleic acid sequences encoding T-cell receptors.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: September 5, 2023
    Inventors: Xi Chen, Ely Porter
  • Patent number: 11737436
    Abstract: Two or more conditional, dominant, lethal gene expression systems provide high levels of penetrance in insects. Lethality is induced at an earlier stage of development and the risk of biochemical resistance is reduced, as compared to a single insect conditional, dominant, lethal gene expression system. The invention is useful for the control of insect populations.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: August 29, 2023
    Assignee: Oxitec Limited
    Inventors: Martha Koukidou, Luke Alphey, Simon Warner
  • Patent number: 11733235
    Abstract: In one aspect, disclosed herein is a method for evaluating the immunogenicity of a test substance in a short period of time by using, as an indicator of the immunogenicity of the test substance, the proportion of IL-2-secreting cells in a T cell population (preferably a CD4+ T cell population) at a time point during the early stage of IL-2 secretion after stimulation of the T cell population with the test substance (preferably 24 hours to 72 hours after the stimulation with the test substance).
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: August 22, 2023
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Chiyomi Kubo, Shigeki Motoyama, Yoshiyuki Arata
  • Patent number: 11730743
    Abstract: Therapeutic uses P2X7 inhibition and inhibition of IRAK1 and/or IRAK4, methods protecting a cell, and screening methods for identifying inhibitors are described herein.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: August 22, 2023
    Assignee: University of Kentucky Research Foundation
    Inventor: Jayakrishna Ambati
  • Patent number: 11718827
    Abstract: Some embodiments of the disclosure use human peripheral blood for ctDNA sequencing or tumor tissues for whole exome sequencing, screen out mutation sites to perform antigen epitope prediction, connect and synthesize an expression gene sequence of mutant peptides. Other embodiments of the disclosure construct a lentiviral vector, package the lentivirus, transfect an APC cell to complete transformation of a specific LV cell, co-culture in vitro with PBMC separated from the peripheral blood, screen out an effective polypeptide, and transform common T cells into RFF cells. Suppressive signaling molecules include one or more of PD-1, Tim-3, LAG3, CTLA-4, BTLA, VISTA, CD160, and 2B4 (CD244). Antigen presenting cells include one or more of PBMC, a dendritic cell, neutrophil, B lymphocyte, and macrophage.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: August 8, 2023
    Assignees: Beijing DCTY Biotech Co., Ltd.
    Inventors: Shunchang Jiao, Rong Zhang, Tianfu Zhang, Zishan Zhou, Jiasen Xie, Ziming Wu, Gang Peng
  • Patent number: 11706177
    Abstract: Provided herein are CRISPR/Cas methods and compositions for targeting RNA molecules, which can be used to detect, edit, or modify a target RNA.
    Type: Grant
    Filed: April 1, 2022
    Date of Patent: July 18, 2023
    Assignee: Salk Institute for Biological Studies
    Inventors: Patrick D. Hsu, Silvana Konermann
  • Patent number: 11697828
    Abstract: Compositions and methods are provided for creating and promoting biallelic targeted modifications to genomes within cells and for producing non-human animals comprising the modified genomes. Also provided are compositions and methods for modifying a genome within a cell that is heterozygous for an allele to become homozygous for that allele. The methods make use of Cas proteins and two or more guide RNAs that target different locations within the same genomic target locus. Also provided are methods of identifying cells with modified genomes.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: July 11, 2023
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: David Frendewey, Ka-Man Venus Lai, Wojtek Auerbach, Gustavo Droguett, Anthony Gagliardi, David M. Valenzuela, Vera Voronina, Lynn Macdonald, Andrew J. Murphy, George D. Yancopoulos
  • Patent number: 11692186
    Abstract: The present invention provides a snake venom thrombin marker peptide of Agkistrodon Halys Pallas and an application of the snake venom thrombin-like enzyme in identifying species of Hemocoagulase for Injection. The application includes the following steps of: dissolving a to-be-detected sample and a reference substance of the marker peptide respectively to prepare a test solution and a reference solution, and conducting alkylation reduction on the test solution and the reference solution with dithiothreitol and iodoacetamide; after diluting products with an ammonium bicarbonate solution, adding enzyme for hydrolysis; and after enzymolysis is finished, conducting centrifugation at a high speed, and injecting a supernatan into a liquid chromatography-mass spectrometer for analysis. This method is simple, convenient and rapid, is strong in specificity, fills the gap in identifying the source of species of the snake venom thrombin-like enzyme of Agkistrodon Halys Pallas and improves the quality control level.
    Type: Grant
    Filed: July 30, 2021
    Date of Patent: July 4, 2023
    Assignees: Shandong University, Shandong Institute for Food and Drug Control, Avanc Pharmaceutical Co., Ltd
    Inventors: Ruiqing Xian, Feng Shi, Liping Gong, Lianli Chi, Qunye Zhang, Weijian Wang, Hongming Du, Congcong Wang, Baojian Hang, Fengshan Wang
  • Patent number: 11680245
    Abstract: Innate lymphoid cells (ILCs) represent innate versions of T helper and cytotoxic T cells that differentiate from committed ILC precursors (ILCP). Still, how ILCP relate to mature tissue-resident ILCs remains unclear. ILCP that are present in the blood and all tested lymphoid and non-lymphoid human tissues were identified. Human ILCP fail to express the signature transcription factors (TF) and cytokine outputs of mature NK cells and ILCs but are epigenetically poised to do so. Human ILCP robustly generate all ILC subsets in vitro and in vivo. While human ILCP express RAR related orphan receptor C (RORC), circulating ILCP can be found in RORC-deficient patients that retain potential for EOMES+ NK cells, T-BET+ ILC1, GATA-3+ ILC2 and for IL-22+ but not for IL-17A+ ILC3. A model of tissue ILC differentiation (‘ILC-poiesis’) is proposed whereby diverse ILC subsets are generated in situ from ILCP in response to environmental stressors, inflammation and infection.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: June 20, 2023
    Inventors: James Di Santo, Ai Ing Lim
  • Patent number: 11674952
    Abstract: Compositions and methods disclosed concern an isogenic population of in vitro human embryonic stem cells comprising a disease form of the Huntingtin gene (HTT) at the endogenous HTT gene locus in the genome of the cell; wherein the disease form of the HTT gene comprises a polyQ repeat of at least 40 glutamines at the N-terminus of the Huntingtin protein (HTT). The cell lines of the disclosure comprise genetically-defined alterations made in the endogenous HTT gene that recapitulate Huntington's Disease in humans. Furthermore, the cell lines have isogenic controls that share a similar genetic background. Differentiating cell lines committed to a neuronal fate and fully differentiated cell lines are also provided and they also display phenotypic abnormalities associated with the length of the polyQ repeat of the HTT gene. These cell lines are used as screening tools in drug discovery and development to identify substances that fully or partially revert these phenotype abnormalities.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: June 13, 2023
    Assignee: The Rockefeller University
    Inventors: Ali Brivanlou, Albert Ruzo, Alessia Deglincerti, Tomomi Haremaki, Fred Etoc
  • Patent number: 11666051
    Abstract: The present disclosure describes a DNA fragment mixture for the prevention or for the treatment of at least one pathogenic, parasitic or infesting species of plants or of the environment, wherein the DNA mixture consists of random fragments of total DNA of at least one pathogenic, parasitic, or infesting species, and/or at least one phylogenetically similar species, against which the prevention and treatment are directed. Further, the disclosure describes a process and related system for improvement of the production/growth of microorganisms at high yield in bioreactors or photobioreactors, or of plants in different culture systems, where the nucleic acids of the organisms produced/grown by such a process are removed from the culture medium and the culture medium, deprived of these nucleic acid, is used again in the process.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: June 6, 2023
    Assignee: NO SELF S.R.L.
    Inventor: Stefano Mazzoleni
  • Patent number: 11649468
    Abstract: Disclosed herein are methods and compositions for targeted integration of an exogenous sequence into the human PPP1R12C locus, for example, for expression of a polypeptide of interest.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: May 16, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Russell DeKeiver, Philip D. Gregory, David Paschon, Phillip Tam, Fyodor Urnov
  • Patent number: 11603570
    Abstract: Disclosed are: (i) methods for identifying leukemia patients who (or leukemia cells that) do not exhibit an MLL-translocation, rearrangement or MLL-partial tandem duplication but who are nonetheless susceptible to treatment with DOT1L inhibitors; and (ii) methods for treating leukemia patients who (or inhibiting proliferation or inducing apoptosis of leukemia cells that) do not exhibit an MLL-translocation, rearrangement or MLL-partial tandem duplication with DOT1L inhibitors. The patients identified as susceptible and the patients (or cells) treated exhibit elevated expression of a IIOX cluster gene or of a HOX cluster-associated gene. Elevated expression of such genes can be measured, e.g.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: March 14, 2023
    Inventor: Scott A. Armstrong
  • Patent number: 11604184
    Abstract: The invention relates to biomarkers in children's skin, in particular in the skin of infants, the expression of which changes when the skin is affected by atopic dermatitis. Such markers are particularly advantageous in that they allow the skin's response to atopic dermatitis to be monitored. The inventors have developed methods for evaluating the in vitro efficacy of formulations in preventing the effects of atopic dermatitis on a child's skin, using a skin model specifically capable of reproducing the characteristics of children's skin.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: March 14, 2023
    Assignee: Laboratoires Expanscience
    Inventors: Caroline Baudouin, Stephanie Bredif